Financial Toxicity for Pembrolizumab and Atezolizumab for Metastatic Non-Small Cell Lung Cancer: A Pooled Analysis of Cost-Effectiveness Analyses
Immunotherapy could bring financial toxicity, and financial toxicity assessment during clinical decision would weaken the potential impact in the whole course of immunotherapy.
Authors
- Kai Xu (ORCID: https://orcid.org/0000-0003-0154-5830)
- Zi-Jia Chen
- Weijia Huang (ORCID: https://orcid.org/0000-0002-3620-5038)
- Jia-Hui Weng
- Qinghua Zhou (ORCID: https://orcid.org/0000-0002-3344-5175)
- Yifeng Wang (ORCID: https://orcid.org/0009-0009-2211-9233)
- Jiewei Liu (ORCID: https://orcid.org/0009-0009-8265-8984)
- Xianglin Zhu
Institutions
- Sichuan University (CN)
- West China Medical Center of Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
Publication Details
- Journal
- Risk Management and Healthcare Policy
- Published
- 2025-03-01
- DOI
- https://doi.org/10.2147/rmhp.s504442
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Department of Science and Technology of Sichuan Province